Skip to main content
NervGen Pharma Corp. logo

NervGen Pharma Corp. — Investor Relations & Filings

Ticker · NGEN ISIN · CA64082X2032 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 325 across all filing types
Latest filing 2025-04-03 Regulatory Filings
Country CA Canada
Listing TSXV NGEN

About NervGen Pharma Corp.

https://nervgen.com/

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on the discovery and development of pharmaceutical treatments designed to promote nervous system repair following neurologic trauma and disease. The company's core mission is to enable the nervous system to repair itself, offering a pharmacologic approach to conditions previously considered irreparable. Its lead drug candidate is NVG-291, a novel therapy currently in Phase 1b/2a clinical trials (CONNECT SCI Study) for individuals living with chronic spinal cord injury (SCI). Recent study data has demonstrated durable improvements in function and quality of life in this patient population. NervGen is also advancing its next-generation candidate, NVG-300, into preclinical proof-of-concept studies for three initial indications, expanding its pipeline for nervous system disorders.

Recent filings

Filing Released Lang Actions
Audited annual financial statements – English.pdf
Regulatory Filings
2025-04-03 English
News release - English.pdf
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing the grant of 545,000 stock options (equity instruments) to employees and consultants, including details on exercise price and vesting schedules. This constitutes a change in the company’s capital structure through the issuance of new equity-linked instruments. It fits the category for Share Issue/Capital Change (SHA).
2025-03-15 English
Notice of the meeting and record date - English.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice from the transfer agent to securities regulators providing key details (record date, meeting date, location, proxy delivery statuses) for an upcoming Annual General Meeting of security holders. It is not the AGM presentation materials themselves, nor an annual report or results release. This type of communication is part of the proxy solicitation process – delivering meeting notices and related information to shareholders. Therefore, it aligns with the Proxy Solicitation & Information Statement category (PSI).
2025-03-03 English
News release - English.pdf
Share Issue/Capital Change Classification · 1% confidence The document is a company press release announcing the grant of incentive stock options to employees and officers. This relates to a change in the company’s capital structure via option issuance, not a share buyback or an insider transaction. Thus it fits the “Share Issue/Capital Change” category (SHA).
2025-02-18 English
News release - English.pdf
Notice of Dividend Amount Classification · 0% confidence The document is a press release announcing that Rogers Sugar Inc.’s Board has authorized a quarterly dividend of $0.09 per share, specifying the record date and payment date. This matches the definition of a Notice of Dividend Amount (DIV).
2025-02-06 English
News release - English.pdf
Regulatory Filings Classification · 0% confidence The document is a corporate press release announcing clinical trial enrollment and dosing milestones, with no financial results, voting, dividends, share actions, or regulatory report attachments. It does not fit specific categories such as earnings release, annual/interim report, or management changes. Therefore, it falls under the fallback miscellaneous/regulatory announcement category (RNS).
2025-02-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.